<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:02:38Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5067545" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5067545</identifier><datestamp>2016-10-25</datestamp><setSpec>neurology</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Neurology</journal-id>
      <journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
      <journal-id journal-id-type="hwp">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">neur</journal-id>
      <journal-id journal-id-type="pmc">neurology</journal-id>
      <journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
      <journal-title-group>
        <journal-title>Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0028-3878</issn>
      <issn pub-type="epub">1526-632X</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
        <publisher-loc>Hagerstown, MD</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5067545</article-id>
      <article-id pub-id-type="pmcid">PMC5067545</article-id>
      <article-id pub-id-type="pmc-uid">5067545</article-id>
      <article-id pub-id-type="pmid">27629094</article-id>
      <article-id pub-id-type="publisher-id">NEUROLOGY2016735225</article-id>
      <article-id pub-id-type="doi">10.1212/WNL.0000000000003212</article-id>
      <article-categories>
        <subj-group subj-group-type="hwp-journal-coll">
          <subject>91</subject>
          <subject>176</subject>
          <subject>178</subject>
          <subject>181</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>SIGMAR1</italic> mutation associated with autosomal recessive Silver-like syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Horga</surname>
            <given-names>Alejandro</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="author-notes" rid="fn1">*</xref>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tomaselli</surname>
            <given-names>Pedro J.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="author-notes" rid="fn1">*</xref>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>Brazilian National Council for Scientific and Technological Development (CNPq),205854/2014-1, research, 2015.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gonzalez</surname>
            <given-names>Michael A.</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>LaurÃ </surname>
            <given-names>Matilde</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NINDS/ORD (1U54NS065712-01), 2010-2013</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muntoni</surname>
            <given-names>Francesco</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>(1) AVI Biopharma, Scientific Advisory Board, 2009-2010; (2) GSK, Scientific Advisory Board, 2011 (x1) (3) Pfizer, Scientific Advisory Board 2014 (x1) (4) Sarepta, Scientific advisory board 2014 (x1) (5) Roche, Scientific advisory Board 2013 (x1) (6) PTC Therapeutics, Scientific Advisory board 2013 and 2014 (x2) (7) Summit Scientific Advisory Board 2013 (x2)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>(1) Neuromuscular Disorders, Editorial Board; (2) Neuropaediatrics, Editorial Board</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>Duchenne muscular dystrophy. Oxford University Press, 2003</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>Pfizer 2014</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>Sarepta Symposium, International Neuromuscular Meeting Nice 2014 PTC Symposium, International Neuromuscular Meeting Nice 2014 Roche Symposium on SMA, Vienna 2015</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>(1) Ionis (grant to UCL); (2) PTC124 (grant to UCL); (3) Biomarin grant to UCL); (4) Roche (grant to UCL); (5) Summit plc (grant to UCL);</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>(1) Wellcome Trust, (2) EU-FP7, (3) Medical Research Council, (4) Muscular Dystrophy Campaign, (5) Muscular Dystrophy Association USA, (6) SMA Trust; (8) AFM, (9) NIHR, (10) British Heart Foundation</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>SMA TRUST grant to UCL</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manzur</surname>
            <given-names>Adnan Y.</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for travel or speaker honoraria:</title>
                <list-item>
                  <p>travel funded to ENMC workshop on Duchenne Muscular Dystrophy (By the organising ENMC European Neuromuscular Centre) in Dec 2010</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NHS consultant at Great Ormond Street Hospital Trust London - main full time job</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other activities:</title>
                <list-item>
                  <p>Lead clinician for UK North Star Clinical Network and National Neuromuscular Database - unpaid job part of NHS work</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hanna</surname>
            <given-names>Michael G.</given-names>
          </name>
          <degrees>FRCP</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>novartis</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>(1) MRC Centre Grant, MR/K000608/1. (2) The Myositis Support Group.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blake</surname>
            <given-names>Julian C.</given-names>
          </name>
          <degrees>MRCP</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Houlden</surname>
            <given-names>Henry</given-names>
          </name>
          <degrees>PhD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>My laboratory is funded by: The Medical Research Council (MRC) UK, The BRT, The MDA USA, Muscular Dystrophy UK, Rosetrees Trust, The Wellcome Trust and the National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>My laboratory is funded by: The Dystonia Medical Research Foundation (DMRF), The Parkinson's Disease Foundation (PDF), National Organisation for Rare Disorders (NORD) and The Brain Research Trust (BRT). The National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>ZÃ¼chner</surname>
            <given-names>Stephan</given-names>
          </name>
          <degrees>MD</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Reilly</surname>
            <given-names>Mary M.</given-names>
          </name>
          <degrees>FRCP</degrees>
          <author-comment content-type="disclosure">
            <p>
              <list list-type="order">
                <title>Scientific Advisory Boards:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Gifts:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Funding for Travel or Speaker Honoraria:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Editorial Boards:</title>
                <list-item>
                  <p>(1) Brain, Editorial Board, appointed 2008; (2) Neuromuscular Disorders, Editorial Board, appointed 2005; (3) Journal of the Peripheral Nervous System, Editorial Board, appointed 2005 (4) editorial board JNNP (current)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Patents:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Publishing Royalties:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Employment, Commercial Entity:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Consultancies:</title>
                <list-item>
                  <p>(1)Commercial entity: One off consultancy for Servier January 2016 on subject not related to this submission.</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Speakers' Bureaus:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Other Activities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Clinical Procedures or Imaging Studies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Commercial Entities:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Government Entities:</title>
                <list-item>
                  <p>NIH grant U54NS065712 MRC centre grant G0601943</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Academic Entities:</title>
                <list-item>
                  <p>? CLRN grant to support NIH RDCRC natural history study (PI) (2011-2012) ? MRC - Using Next Generation Sequencing to investigate neuromuscular disorders. Project grant (CO- PI) (2011-2014) ? Wellcome Trust ? A next generation sequencer for the Institute of Neurology. Equipment Grant? (CO-PI) (2011 ? 2016) ? UCL CBRC ? A next generation sequencer for the Institute of Neurology. Capital bid (CO-PI) (2011-2016) ? Ipsen training grant for Dr. Alex Rossor (2010-2011). ? NIHR Doctoral Research Training Fellowship for Dr. Taibish Saifee ?The clinical spectrum and pathophysiology of tremor in peripheral neuropathy? (Supervisor) (2010-2013) ? Muscular Dystrophy Association (US) grant ?Genetic Modifiers of the CMT1A phenotype? (Mentor on development grant for Henry Houlden) (2009-2012) ? Muscular dystrophy campaign grant ?Strengthening Hip Flexors to improve walking distance in people with Charcot-Marie-Tooth disease? (PI) (2008-2010) ? UCLH / UCL Comprehensive Biomedical Research Centre ?Investigation of the genes responsible for Charcot Marie tooth disease and related disorders in a UK population and development/implementation of diagnostic guidelines and genetic testing? (PI) (2008-2010) ? CRDC project grant ?Pathomechanism and possible treatment strategies for distal hereditary neuropathies secondary to HSP27 mutations (CO-PI) (2008-2010) ? Muscular Dystrophy campaign centre grant ?Combined Dubowitz and Institute of Neurology neuromuscular centre grant (CO-PI) (2008-2011)</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Research Support, Foundations and Societies:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options/Board of Directors Compensation:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>License Fee Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Royalty Payments, Technology or Inventions:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Research Sponsor:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
            <p>
              <list list-type="order">
                <title>Legal Proceedings:</title>
                <list-item>
                  <p>NONE</p>
                </list-item>
              </list>
            </p>
          </author-comment>
        </contrib>
        <aff>From the MRC Centre for Neuromuscular Diseases (A.H., P.J.T., M.L., M.G.H., J.C.B., H.H., M.M.R.), UCL Institute of Neurology, Queen Square, London, UK; Department of Human Genetics and Hussman Institute for Human Genomics (M.A.G., S.Z.), Miller School of Medicine, University of Miami; The Genesis Project Foundation (M.A.G.), Miami, FL; The Dubowitz Neuromuscular Centre (F.M., A.Y.M.), UCL Institute of Child Health, London; and Department of Clinical Neurophysiology (J.C.B.), Norfolk and Norwich University Hospital, Norwich, UK.</aff>
      </contrib-group>
      <author-notes>
        <corresp>Correspondence to Dr. Reilly: <email>m.reilly@ucl.ac.uk</email></corresp>
        <fn fn-type="financial-disclosure">
          <p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003212">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by MRC.</p>
        </fn>
        <fn fn-type="other" id="fn1">
          <label>*</label>
          <p>These authors contributed equally to this work.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>11</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
      <volume>87</volume>
      <issue>15</issue>
      <fpage>1607</fpage>
      <lpage>1612</lpage>
      <history>
        <date date-type="received">
          <day>29</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>6</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2016 American Academy of Neurology</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>American Academy of Neurology</copyright-holder>
        <license license-type="open-access">
          <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:title="pdf" xlink:href="NEUROLOGY2016735225.pdf"/>
      <abstract>
        <sec>
          <title>Objective:</title>
          <p>To describe the genetic and clinical features of a simplex patient with distal hereditary motor neuropathy (dHMN) and lower limb spasticity (Silver-like syndrome) due to a mutation in the sigma nonopioid intracellular receptorâ1 gene (<italic>SIGMAR1</italic>) and review the phenotypic spectrum of mutations in this gene.</p>
        </sec>
        <sec>
          <title>Methods:</title>
          <p>We used whole-exome sequencing to investigate the proband. The variants of interest were investigated for segregation in the family using Sanger sequencing. Subsequently, a larger cohort of 16 unrelated dHMN patients was specifically screened for <italic>SIGMAR1</italic> mutations.</p>
        </sec>
        <sec>
          <title>Results:</title>
          <p>In the proband, we identified a homozygous missense variant (c.194T&gt;A, p.Leu65Gln) in exon 2 of <italic>SIGMAR1</italic> as the probable causative mutation. Pathogenicity is supported by evolutionary conservation, in silico analyses, and the strong phenotypic similarities with previously reported cases carrying coding sequence mutations in <italic>SIGMAR1</italic>. No other mutations were identified in 16 additional patients with dHMN.</p>
        </sec>
        <sec>
          <title>Conclusions:</title>
          <p>We suggest that coding sequence mutations in <italic>SIGMAR1</italic> present clinically with a combination of dHMN and pyramidal tract signs, with or without spasticity, in the lower limbs. Preferential involvement of extensor muscles of the upper limbs may be a distinctive feature of the disease. These observations should be confirmed in future studies.</p>
        </sec>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source>MRC</funding-source>
          <award-id>G0601943</award-id>
        </award-group>
        <award-group>
          <funding-source>National Institutes of Neurologic Diseases and Stroke and Office of Rare Diseases</funding-source>
          <award-id>U54NS065712</award-id>
        </award-group>
        <award-group>
          <funding-source>INC</funding-source>
          <award-id>U54NS065712</award-id>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>special-property</meta-name>
          <meta-value>video</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body><p>The distal hereditary motor neuropathies (dHMN) comprise a heterogeneous group of diseases that share the common feature of slowly progressive, symmetrical, and distal-predominant neurogenic weakness and amyotrophy.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> There is phenotypic and genetic overlap between dHMN and other hereditary neuropathies and motor neuron disorders such as axonal forms of Charcot-Marie-Tooth disease (CMT2), juvenile amyotrophic lateral sclerosis (ALS), and hereditary spastic paraplegia (HSP). <italic>BSCL2</italic>- and <italic>REEP1</italic>-related disorders are an example of this overlap as autosomal dominant mutations in these genes can cause dHMN with upper limb predominance, pure HSP, or spastic paraplegia with amyotrophy of hands (Silver syndrome) or hands and feet (<xref ref-type="table" rid="T1">table 1</xref>).<sup><xref rid="R2" ref-type="bibr">2</xref><xref ref-type="bibr" rid="R3">â</xref><xref rid="R6" ref-type="bibr">6</xref></sup></p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Genes and loci identified in distal hereditary motor neuropathies (dHMN) with upper motor neuron signs or with Silver syndrome</p></caption><graphic xlink:href="NEUROLOGY2016735225TT1"/></table-wrap><p>Homozygous mutations in the sigma nonopioid intracellular receptor-1 gene (<italic>SIGMAR1</italic>) have been reported as a cause of dHMN and juvenile ALS.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Here we describe a patient with a Silver-like syndrome carrying a homozygous mutation in <italic>SIGMAR1</italic> and review the phenotypic spectrum of mutations in this gene. We suggest that coding sequence mutations present clinically with a combination of dHMN and pyramidal tract signs, with or without spasticity, in the lower limbs, adding <italic>SIGMAR1</italic> to the list of genes that can cause overlapping motor neuron/nerve phenotypes.</p><sec sec-type="methods" id="s1"><title>METHODS</title><p>The proband and 16 additional patients screened for <italic>SIGMAR1</italic> mutations were identified from those attending neuropathy clinics at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. The proband was investigated as part of a larger study to determine the genetic etiology in patients with inherited neuropathies using whole-exome sequencing (WES). All patients had undergone clinical and instrumental assessments during the routine diagnostic process and mutations in common neuropathy-related genes had been excluded in all cases. Nerve conduction studies, EMG, laboratory tests, and MRI scans were performed using standard methods. WES, Sanger sequencing, and in silico analysis methods are detailed in the supplementary material at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003212">Neurology.org</ext-link>.</p><sec id="s1-1"><title>Standard protocol approvals, registration, and patient consents.</title><p>The study had ethical approval from the National Hospital for Neurology &amp; Neurosurgery/Institute of Neurology Joint Research Ethics Committee. All patients gave written informed consent for genetic testing.</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Clinical features.</title><p>The proband (<xref ref-type="fig" rid="F1">figure, A</xref>) was the second child of healthy, nonconsanguineous parents of British and French descent. He walked independently at age 12 months. At age 3 years, he was noted to have bilateral foot drop and frequent falls and, over the following years, he developed progressive muscle weakness and atrophy in the lower limbs. Hand weakness and lower limb stiffness developed during the second decade of life. He underwent orthopedic surgery on his feet at ages 13â14 years and tendon-transfer surgery on both thumbs at ages 16â17 years with good functional outcomes. He has normal intellect, no sensory symptoms, and no sphincter problems. His family history was unremarkable and clinical and electrophysiologic examination of the parents was normal.</p><fig id="F1" orientation="portrait" position="float"><label>Figure</label><caption><title>Family segregation, conservation of the <italic>SIGMAR1</italic> variant, and clinical images of the proband</title><p>(A) Segregation of the <italic>SIGMAR1</italic> variant c.194T&gt;A in the family; genotypes are indicated below tested individuals. (B) Photographs of the proband show atrophy of intrinsic hand muscles, clawed hands, flexed knee posture (characteristic of knee bobbing), and atrophy of leg and foot muscles. (C) Axial T1-weighted MRI of the mid-thighs (left) and mid-legs (right) demonstrate normal appearance of the thigh muscles and atrophy of all lower leg muscles with mild fatty replacement especially of tibialis anterior, tibialis posterior, soleus, and peroneal muscles. (D) Sanger sequencing electropherograms demonstrate sequence variants in the proband and his parents. (E) Conservation of leucine (L) at amino acid position 65 of the Ï-1 receptor encoded by <italic>SIGMAR1</italic>; a subset of 16 species were chosen, representing the 100 species available at the USCS browser.</p></caption><graphic xlink:href="NEUROLOGY2016735225FF1"/></fig><p>At age 17 years, on neurologic examination, he had clawed hands with no fixed contractures, bilateral finger and foot drop, knee bobbing, marked muscle atrophy from mid-forearms and knees down (<xref ref-type="fig" rid="F1">figure, B</xref>), and weakness of wrist extension (Medical Research Council [MRC] grade 2/5 right, 4/5 left), finger extension (1/5), intrinsic hand muscles (0/5), ankle dorsiflexion (0/5 right, 1/5 left), ankle plantar flexion (1/5), toe extension (1/5), and toe flexion (0/5). Muscle strength in proximal muscles and finger flexors was normal. There was marked spasticity of the lower limbs and normal muscle tone in the upper limbs. Deep tendon reflexes were present in the upper limbs, increased at the knees, and absent at the ankles. Babinski sign was present bilaterally. Sensory and cranial nerve examinations were unremarkable. He walked with a combination of spastic and steppage gait. There was no scoliosis. Nerve conduction studies were consistent with a motor axonal neuropathy that was more severe in the lower limbs (table e-1). The superficial peroneal sensory action potential was normal and although the sural sensory nerve action potential amplitude was mildly reduced this may have been due to previous surgery rather than a sensory neuropathy. EMG of the biceps brachii showed features of chronic denervation. Brain and spinal cord MRIs were normal. Charcot-Marie-Tooth Neuropathy Score v.2 was 13.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><p>At age 20, neurologic examination confirmed progression of wrist extension weakness (MRC grade 1/5) causing hand drop and weakness of finger flexion (4/5) (video). The remainder of the examination was unchanged. MRI of the lower limbs demonstrated normal appearance of the thigh muscles and atrophy of all lower leg muscles with mild fatty replacement (<xref ref-type="fig" rid="F1">figure, C</xref>). Serum creatine kinase level was normal at 184 IU/L.</p></sec><sec id="s2-2"><title>Genetic studies.</title><p>Molecular genetic analysis of the 17p11.2 chromosome region and direct sequencing of <italic>MFN2</italic>, <italic>HSPB1</italic>, <italic>HSPB8</italic>, <italic>HSPB3</italic>, <italic>BSCL2,</italic> and <italic>GARS</italic> genes revealed no pathogenic variants. WES on the proband revealed a total of 25,073 exonic variants (table e-2). The GEM.app software was used to focus on nonsynonymous, splice-site, and coding indel variants that were present in &lt;5 families in the GEM.app database and that had a minor allele frequency (MAF) &lt;0.5% in the Exome Variant Server database (<ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>). From a total of 198 variants that met these filtering criteria, 9 of them involved genes associated with pure and complex inherited neuropathies/neuronopathies. Six were heterozygous variants in genes associated with autosomal recessive disorders (<italic>ERCC6</italic>, <italic>LAMA2</italic>, <italic>MTPAP</italic>, <italic>MTTP</italic>, <italic>NTRK1</italic>, and <italic>PRX</italic>). Two heterozygous variants were detected in genes associated with autosomal dominant spinal muscular atrophy and CMT2 (<italic>BICD2</italic> and <italic>TRPV4</italic>) and one homozygous variant was detected in <italic>SIGMAR1</italic>, a gene associated with autosomal recessive dHMN and juvenile ALS. The variants detected in <italic>BICD2</italic>, <italic>TRPV4</italic>, and <italic>SIGMAR1</italic> were validated by direct sequencing.</p><p>Cosegregation analyses allowed exclusion of the <italic>BICD2</italic> and <italic>TRPV4</italic> variants as pathogenic (e-Results) and confirmed that the proband's parents were heterozygous carriers of the <italic>SIGMAR1</italic> variant c.194T&gt;A located in exon 2 (Ensembl ID ENST00000277010) (<xref ref-type="fig" rid="F1">figure, D</xref>). This variant was present in 4 out of 97,910 alleles (MAF 0.004%) in the Exome Aggregation Consortium database (ExAC <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>), with none of the carriers being homozygous, and was absent in the GEM.app database and in an in-house exome database of 138 clinically and neuropathologically normal controls. c.194T&gt;A leads to the substitution of nonpolar leucine for polar glutamine at amino acid position 65 (p.Leu65Gln), affects a highly conserved nucleotide and amino acid (<xref ref-type="fig" rid="F1">figure, E</xref>), and is predicted as being deleterious or disease-causing by pathogenicity prediction tools (table e-3).</p><p>The 4 coding exons, intron/exon boundaries, and the 3â²-untranslated region (3â²-UTR) of <italic>SIGMAR1</italic> were Sanger sequenced in the proband and 16 additional unrelated dHMN patients. No other exonic or intronic changes were identified (table e-4).</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>Using WES in a simplex patient with distal weakness and amyotrophy and lower limb spasticity and electrophysiologic features consistent with a motor neuropathy, we have identified <italic>SIGMAR1</italic> as the probable causative gene. The phenotype of the patient mimics classical Silver syndrome except for the absence of upper limb predominance and the autosomal recessive pattern of inheritance; we termed this novel phenotype Silver-like syndrome. Pathogenicity of the <italic>SIGMAR1</italic> variant is supported by the in silico analysis described above and previous reports of individuals carrying homozygous mutations in the same gene, which are summarized in <xref ref-type="table" rid="T2">table 2</xref>.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup></p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Genetic and clinical features of patients with <italic>SIGMAR1</italic> mutations</p></caption><graphic xlink:href="NEUROLOGY2016735225TT2"/></table-wrap><p>Like the present case, affected individuals from previously reported families developed a combination of distal weakness in the upper Â± lower limbs and pyramidal features in the lower limbs. Both our case and those with the mutation c.304G&gt;C, located in exon 2, presented within the first 3 years of life and had severe involvement of forearm extensors and lower limb spasticity.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Although the authors designated the cases with c.304G&gt;C as juvenile ALS, they had no bulbar involvement and EMG evidence of active denervation is not mentioned in the report. Thus, it appears that all these patients with exon 2 mutations share the same phenotype.</p><p>The cases with dHMN due to the splice-site mutation c.151+1G&gt;T, resulting in deletion of the last 20 amino acids encoded by exon 1, had a later age at onset and lacked spasticity.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> As suggested by the authors, this phenotype is similar to that described in patients with dHMN and pyramidal features identified in the Jerash region of Jordan (dHMN-J) and mapped to 9p21.1-p12, which encompasses <italic>SIGMAR1</italic>.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> It is also significant that, as observed in our patient and those with the mutation c.304G&gt;C, patients with dHMN-J had preferential involvement of forearm extensors over flexors.</p><p>The homozygous variant rs4879809 (9:34635598T&gt;C, c.*31A&gt;G), located in the 3â²-UTR of <italic>SIGMAR1</italic>, has been detected in a consanguineous family with adult-onset ALS.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> The authors suggested that c.*31A&gt;G could contribute to the pathogenesis of ALS in this family. The allele C in 9:34635598, however, has a frequency of 99.5% in the ExAC database (99% homozygotes) and was present in all patients from our cohort and the proband's unaffected parents so we regarded it as nonpathogenic. Heterozygous 3â²-UTR variants in <italic>SIGMAR1</italic> have been also identified in individuals with frontotemporal lobar degenerationâmotor neuron disease but their pathogenic role is still unclear.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup></p><p><italic>SIGMAR1</italic> encodes for the sigma-1 receptor (Ï<sub>1</sub>R), an endoplasmic reticulum (ER) chaperone that resides at the specialized mitochondrial-associated ER membrane.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Ï<sub>1</sub>R is involved in a wide array of cellular processes, including ER-mitochondrial Ca<sup>2+</sup> signaling and cell survival, and is highly expressed in motor neurons of the brainstem and spinal cord.<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> Recent studies suggest that loss of Ï<sub>1</sub>R function causes ERâmitochondria disconnection and ER stress activation and disrupts mitochondrial function and axonal transport, leading to motor neuron axonal degeneration followed by cell death.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> This dying-back degeneration process would be consistent with the distal predominant pattern of motor involvement seen in patients with <italic>SIGMAR1</italic> mutations.</p><p>Based on the present study and previous reports, we propose that coding sequence mutations in <italic>SIGMAR1</italic> manifest clinically with a combination of dHMN and pyramidal tract signs, with or without spasticity, in the lower limbs, and that preferential involvement of forearm extensors may be a distinctive feature of the disease. These observations should be confirmed in future studies.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_15_1607__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000003212_Supplementary_Material.pdf"/>
</supplementary-material>
<supplementary-material id="PMC_2" content-type="local-data">
<caption>
<title>Video</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_87_15_1607_v2_index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000003212_Video_Legend.docx"/>
<media xlink:role="associated-file" mimetype="text" mime-subtype="plain" xlink:href="supp_WNL.0000000000003212_735225.mp4"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn fn-type="supplementary-material">
        <p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003212">Neurology.org</ext-link></p>
      </fn>
    </fn-group>
    <sec sec-type="contributions">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p content-type="contributions">A. Horga, P.J. Tomaselli: study design; acquisition, analysis, and interpretation of data; drafting and revising the manuscript. M.A. Gonzalez: acquisition, analysis, and interpretation of data; revising the manuscript. M. LaurÃ , F. Muntoni, A.Y. Manzur, M.G. Hanna, J.C. Blake, H. Houlden: interpretation of data; revising the manuscript. S. ZÃ¼chner: study concept and design; acquisition, analysis, and interpretation of data; revising the manuscript. M.M. Reilly: study supervision; study concept and design; acquisition, analysis, and interpretation of data; drafting and revising the manuscript.</p>
    </sec>
    <sec sec-type="funding">
      <title>STUDY FUNDING</title>
      <p content-type="funding">Supported by an MRC Center grant (G0601943) and the National Institutes of Neurologic Diseases and Stroke and Office of Rare Diseases (U54NS065712). The INC (U54NS065712) is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). Also supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.</p>
    </sec>
    <sec sec-type="disclosure">
      <title>DISCLOSURE</title>
      <p content-type="disclosure">The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000003212">Neurology.org</ext-link> for full disclosures.</p>
    </sec>
    <glossary>
      <title>GLOSSARY</title>
      <def-list>
        <def-item>
          <term id="G1">ALS</term>
          <def>
            <p>amyotrophic lateral sclerosis</p>
          </def>
        </def-item>
        <def-item>
          <term id="G2">CMT</term>
          <def>
            <p>Charcot-Marie-Tooth disease</p>
          </def>
        </def-item>
        <def-item>
          <term id="G3">dHMN</term>
          <def>
            <p>distal hereditary motor neuropathy</p>
          </def>
        </def-item>
        <def-item>
          <term id="G4">dHMN-J</term>
          <def>
            <p>distal hereditary motor neuropathy and pyramidal features identified in the Jerash region of Jordan</p>
          </def>
        </def-item>
        <def-item>
          <term id="G5">ER</term>
          <def>
            <p>endoplasmic reticulum</p>
          </def>
        </def-item>
        <def-item>
          <term id="G6">ExAC</term>
          <def>
            <p>Exome Aggregation Consortium database</p>
          </def>
        </def-item>
        <def-item>
          <term id="G7">HSP</term>
          <def>
            <p>hereditary spastic paraplegia</p>
          </def>
        </def-item>
        <def-item>
          <term id="G8">MAF</term>
          <def>
            <p>minor allele frequency</p>
          </def>
        </def-item>
        <def-item>
          <term id="G9">MRC</term>
          <def>
            <p>Medical Research Council</p>
          </def>
        </def-item>
        <def-item>
          <term id="G10">Ï1R</term>
          <def>
            <p>sigma-1 receptor</p>
          </def>
        </def-item>
        <def-item>
          <term id="G11">SIGMAR1</term>
          <def>
            <p>sigma nonopioid intracellular receptorâ1 gene</p>
          </def>
        </def-item>
        <def-item>
          <term id="G12">UTR</term>
          <def>
            <p>untranslated region</p>
          </def>
        </def-item>
        <def-item>
          <term id="G13">WES</term>
          <def>
            <p>whole-exome sequencing</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossor</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Kalmar</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Greensmith</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Reilly</surname><given-names>MM</given-names></name></person-group>
<article-title>The distal hereditary motor neuropathies</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2012</year>;<volume>83</volume>:<fpage>6</fpage>â<lpage>14</lpage>.<pub-id pub-id-type="pmid">22028385</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silver</surname><given-names>JR</given-names></name></person-group>
<article-title>Familial spastic paraplegia with amyotrophy of the hands</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>1966</year>;<volume>29</volume>:<fpage>135</fpage>â<lpage>144</lpage>.</mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irobi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Van den Bergh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Merlini</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The phenotype of motor neuropathies associated with BSCL2 mutations is broader than Silver syndrome and distal HMN type V</article-title>. <source>Brain</source>
<year>2004</year>;<volume>127</volume>:<fpage>2124</fpage>â<lpage>2130</lpage>.<pub-id pub-id-type="pmid">15242882</pub-id></mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auer-Grumbach</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schlotter-Weigel</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lochmuller</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation</article-title>. <source>Ann Neurol</source>
<year>2005</year>;<volume>57</volume>:<fpage>415</fpage>â<lpage>424</lpage>.<pub-id pub-id-type="pmid">15732094</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goizet</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Depienne</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Benard</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>REEP1 mutations in SPG31: frequency, mutational spectrum, and potential association with mitochondrial morpho-functional dysfunction</article-title>. <source>Hum Mutat</source>
<year>2011</year>;<volume>32</volume>:<fpage>1118</fpage>â<lpage>1127</lpage>.<pub-id pub-id-type="pmid">21618648</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beetz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pieber</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Hertel</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Exome sequencing identifies a REEP1 mutation involved in distal hereditary motor neuropathy type V</article-title>. <source>Am J Hum Genet</source>
<year>2012</year>;<volume>91</volume>:<fpage>139</fpage>â<lpage>145</lpage>.<pub-id pub-id-type="pmid">22703882</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Saif</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Al-Mohanna</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bohlega</surname><given-names>S</given-names></name></person-group>
<article-title>A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</article-title>. <source>Ann Neurol</source>
<year>2011</year>;<volume>70</volume>:<fpage>913</fpage>â<lpage>919</lpage>.<pub-id pub-id-type="pmid">21842496</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy</article-title>. <source>Neurology</source>
<year>2015</year>;<volume>84</volume>:<fpage>2430</fpage>â<lpage>2437</lpage>.<pub-id pub-id-type="pmid">26078401</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Herrmann</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>McDermott</surname><given-names>MP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease</article-title>. <source>J Peripher Nerv Syst</source>
<year>2011</year>;<volume>16</volume>:<fpage>191</fpage>â<lpage>198</lpage>.<pub-id pub-id-type="pmid">22003934</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christodoulou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zamba</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Tsingis</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel form of distal hereditary motor neuronopathy maps to chromosome 9p21.1-p12</article-title>. <source>Ann Neurol</source>
<year>2000</year>;<volume>48</volume>:<fpage>877</fpage>â<lpage>884</lpage>.<pub-id pub-id-type="pmid">11117544</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ullah</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Ahmad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Raza</surname><given-names>SI</given-names></name>, <etal>et al.</etal></person-group>
<article-title>In silico analysis of SIGMAR1 variant (rs4879809) segregating in a consanguineous Pakistani family showing amyotrophic lateral sclerosis without frontotemporal lobar dementia</article-title>. <source>Neurogenetics</source>
<year>2015</year>;<volume>16</volume>:<fpage>299</fpage>â<lpage>306</lpage>.<pub-id pub-id-type="pmid">26205306</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luty</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Kwok</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Dobson-Stone</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</article-title>. <source>Ann Neurol</source>
<year>2010</year>;<volume>68</volume>:<fpage>639</fpage>â<lpage>649</lpage>.<pub-id pub-id-type="pmid">21031579</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickering-Brown</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hardy</surname><given-names>J</given-names></name></person-group>
<article-title>Is SIGMAR1 a confirmed FTD/MND gene?</article-title>
<source>Brain</source>
<year>2015</year>;<volume>138</volume>:<fpage>e393</fpage>.<pub-id pub-id-type="pmid">26088964</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayashi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>TP</given-names></name></person-group>
<article-title>Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival</article-title>. <source>Cell</source>
<year>2007</year>;<volume>131</volume>:<fpage>596</fpage>â<lpage>610</lpage>.<pub-id pub-id-type="pmid">17981125</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mavlyutov</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Epstein</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Andersen</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Ziskind-Conhaim</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ruoho</surname><given-names>AE</given-names></name></person-group>
<article-title>The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons: an anatomical and behavioral study</article-title>. <source>Neuroscience</source>
<year>2010</year>;<volume>167</volume>:<fpage>247</fpage>â<lpage>255</lpage>.<pub-id pub-id-type="pmid">20167253</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernard-Marissal</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Medard</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Azzedine</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chrast</surname><given-names>R</given-names></name></person-group>
<article-title>Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration</article-title>. <source>Brain</source>
<year>2015</year>;<volume>138</volume>:<fpage>875</fpage>â<lpage>890</lpage>.<pub-id pub-id-type="pmid">25678561</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>